Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pacira BioSciences Q1 2024 Adj EPS $0.62, Inline, Sales $167.117M Beat $165.351M Estimate

Author: Benzinga Newsdesk | May 07, 2024 04:02pm

Pacira BioSciences (NASDAQ:PCRX) reported quarterly Adj earnings of $0.62 per share which met the analyst consensus estimate. The company reported quarterly sales of $167.117 million which beat the analyst consensus estimate of $165.351 million by 1.07 percent. This is a 4.23 percent increase over sales of $160.341 million the same period last year.

Posted In: PCRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist